Structure Therapeutics’ (GPCR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a report released on Tuesday,Benzinga reports. The firm currently has a $80.00 price target on the stock.

A number of other equities analysts also recently commented on GPCR. William Blair began coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating on the stock. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target on the stock. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Price Performance

GPCR stock opened at $23.65 on Tuesday. Structure Therapeutics has a 1 year low of $13.22 and a 1 year high of $62.74. The firm has a market capitalization of $1.36 billion, a PE ratio of -31.96 and a beta of -1.35. The business has a 50 day simple moving average of $20.14 and a 200-day simple moving average of $27.99.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, equities research analysts expect that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd raised its holdings in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after buying an additional 553 shares during the period. GAMMA Investing LLC boosted its stake in shares of Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after purchasing an additional 1,122 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Structure Therapeutics in the fourth quarter valued at approximately $34,000. FNY Investment Advisers LLC purchased a new stake in Structure Therapeutics during the 4th quarter worth approximately $40,000. Finally, Virtus ETF Advisers LLC boosted its position in Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock valued at $61,000 after buying an additional 455 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.